



Gilbert syndrome

Gilbert syndrome is a relatively mild condition characterized by periods of elevated levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Bilirubin, which has an orange-yellow tint, is produced when red blood cells are broken down. This substance is removed from the body only after it undergoes a chemical reaction in the liver, which converts the toxic form of bilirubin (unconjugated bilirubin) to a nontoxic form called conjugated bilirubin. People with Gilbert syndrome have a buildup of unconjugated bilirubin in their blood (unconjugated hyperbilirubinemia). In affected individuals, bilirubin levels fluctuate and very rarely increase to levels that cause jaundice, which is yellowing of the skin and whites of the eyes.

Gilbert syndrome is usually recognized in adolescence. If people with this condition have episodes of hyperbilirubinemia, these episodes are generally mild and typically occur when the body is under stress, for instance because of dehydration, prolonged periods without food (fasting), illness, vigorous exercise, or menstruation. Some people with Gilbert syndrome also experience abdominal discomfort or tiredness. However, approximately 30 percent of people with Gilbert syndrome have no signs or symptoms of the condition and are discovered only when routine blood tests reveal elevated unconjugated bilirubin levels.

Frequency

Gilbert syndrome is a common condition that is estimated to affect 3 to 7 percent of Americans.

Genetic Changes

Changes in the *UGT1A1* gene cause Gilbert syndrome. This gene provides instructions for making the bilirubin uridine diphosphate glucuronosyltransferase (bilirubin-UGT) enzyme, which is found primarily in liver cells and is necessary for the removal of bilirubin from the body.

The bilirubin-UGT enzyme performs a chemical reaction called glucuronidation. During this reaction, the enzyme transfers a compound called glucuronic acid to unconjugated bilirubin, converting it to conjugated bilirubin. Glucuronidation makes bilirubin dissolvable in water so that it can be removed from the body.

Gilbert syndrome occurs worldwide, but some mutations occur more often in particular populations. In many populations, the most common genetic change that causes Gilbert syndrome (known as *UGT1A1**28) occurs in an area near the *UGT1A1* gene called the promoter region, which controls the production of the bilirubin-UGT enzyme. This genetic change impairs enzyme production. However, this change is uncommon in

Asian populations, and affected Asians often have a mutation that changes a single protein building block (amino acid) in the bilirubin-UGT enzyme. This type of mutation, known as a missense mutation, results in reduced enzyme function.

People with Gilbert syndrome have approximately 30 percent of normal bilirubin-UGT enzyme function. As a result, unconjugated bilirubin is not glucuronidated quickly enough. This toxic substance then builds up in the body, causing mild hyperbilirubinemia.

Not everyone with the genetic changes that cause Gilbert syndrome develops hyperbilirubinemia, indicating that additional factors, such as conditions that further hinder the glucuronidation process, may be necessary for development of the condition. For example, red blood cells may break down too easily, releasing excess amounts of bilirubin that the impaired enzyme cannot keep up with. Alternatively, movement of bilirubin into the liver, where it would be glucuronidated, may be impaired. These other factors may be due to changes in other genes.

Inheritance Pattern

Gilbert syndrome can have different inheritance patterns. When the condition is caused by the *UGT1A1**28 change in the promoter region of the *UGT1A1* gene, it is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have the mutation. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

When the condition is caused by a missense mutation in the *UGT1A1* gene, it is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. A more severe condition known as Crigler-Najjar syndrome occurs when both copies of the *UGT1A1* gene have mutations.

Other Names for This Condition

- constitutional liver dysfunction
- familial nonhemolytic jaundice
- Gilbert disease
- Gilbert-Lereboullet syndrome
- Gilbert's disease
- Gilbert's syndrome
- hyperbilirubinemia 1
- Meulengracht syndrome
- unconjugated benign bilirubinemia

Diagnosis & Management

Genetic Testing

- Genetic Testing Registry: Gilbert's syndrome
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0017551/>

General Information from MedlinePlus

- Diagnostic Tests
<https://medlineplus.gov/diagnostictests.html>
- Drug Therapy
<https://medlineplus.gov/drugtherapy.html>
- Genetic Counseling
<https://medlineplus.gov/geneticcounseling.html>
- Palliative Care
<https://medlineplus.gov/palliativecare.html>
- Surgery and Rehabilitation
<https://medlineplus.gov/surgeryandrehabilitation.html>

Additional Information & Resources

MedlinePlus

- Encyclopedia: Bilirubin – blood
<https://medlineplus.gov/ency/article/003479.htm>
- Encyclopedia: Gilbert's disease
<https://medlineplus.gov/ency/article/000301.htm>
- Health Topic: Jaundice
<https://medlineplus.gov/jaundice.html>
- Health Topic: Liver Diseases
<https://medlineplus.gov/liverdiseases.html>

Genetic and Rare Diseases Information Center

- Gilbert syndrome
<https://rarediseases.info.nih.gov/diseases/6507/gilbert-syndrome>

Educational Resources

- MalaCards: gilbert syndrome
http://www.malacards.org/card/gilbert_syndrome
- Orphanet: Gilbert syndrome
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=357

Patient Support and Advocacy Resources

- American Liver Foundation
<http://www.liverfoundation.org/>
- National Organization for Rare Disorders (NORD)
<https://rarediseases.org/rare-diseases/gilbert-syndrome/>

ClinicalTrials.gov

- ClinicalTrials.gov
<https://clinicaltrials.gov/ct2/results?cond=%22Gilbert+syndrome%22>

Scientific Articles on PubMed

- PubMed
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28Gilbert+Disease%5BMAJR%5D%29+AND+%28Gilbert+syndrome%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D>

OMIM

- GILBERT SYNDROME
<http://omim.org/entry/143500>

Sources for This Summary

- Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *N Engl J Med*. 1995 Nov 2;333(18):1171-5.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/7565971>
- Bosma PJ. Inherited disorders of bilirubin metabolism. *J Hepatol*. 2003 Jan;38(1):107-17. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/12480568>
- Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. *Eur J Pediatr*. 2012 Jan;171(1):11-5. doi: 10.1007/s00431-011-1641-0. Epub 2011 Dec 9. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22160004>
- Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. *Pharmacogenet Genomics*. 2007 Dec;17(12):1017-29.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/18004206>

Reprinted from Genetics Home Reference:

<https://ghr.nlm.nih.gov/condition/gilbert-syndrome>

Reviewed: February 2012

Published: March 21, 2017

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services